

TRISTATE REGIONAL LIVER TRANSPLANT ANESTHESIOLOGY CONFERENCE



Society for the Advancement of Transplant Anesthesia (SATA)

SATURDAY, APRIL 24, 2021

09:00 AM TO 2:00 PM

This SATA regional meeting is to provide the audience the updated knowledge on several critical management issues in abdominal transplant patients.

Virtual meeting: Join Zoom Meeting-

<https://zoom.us/j/95986026411?pwd=V0MwVmJFT204aXUwTm12SzZOUWlzdz09>

<https://tinyurl.com/crsu26ur>

Meeting ID: 959 8602 6411

Passcode: 222873

One tap mobile: +12034329666,,95986026411# US (Bridgeport)

8887880099,,95986026411# US Toll-free

9:00 - 9:15: Welcome –*Gebhard Wagener, MD; Columbia University Irving Medical Center*

9:15 - 10:30 Moderator: *Christine Lennon, MD; Weill Cornell Medicine*

- Hyponatremia in Liver Transplantation
Gebhard Wagener, MD; Columbia University Irving Medical Center
- Pro/con transplant during COVID
Pro: *Parissa Tabrizian, MD; Mount Sinai Medical Center*
Con: *Gebhard Wagener, MD; Columbia University Irving Medical Center*
- Alcoholic hepatitis and transplant controversies
James Park, MD; New York University

10:30 – 11:00: Break

11:00-12:15. Moderator: *Kevin Fitzmartin MD; Montefiore Medical Center*

- Machine perfusion, updates and perspective
Juan P. Rocca, MD; Montefiore Medical Center
- Cardiac Arrest during liver transplantation
Ted Sakai, MD; University of Pittsburgh Medical Center
- What's new in coagulation and transfusion management
Nicolette Schlichting, MD; Mount Sinai Medical Center

12:15-12:30 Break

12:30-1:45: Case discussions: Case based discussion with expert panel

Moderator: *Tricia Brentjens MD; Columbia University Irving Medical Center*

- Acute liver failure: ICU case presentation
Uyen To MD. Yale School of Medicine
- Porto-pulmonary hypertension: Intraoperative management and outcome
Nikhil Chawla MD. Yale School of Medicine
- Hepatic artery pseudoaneurysm: Case presentation
Shreyajit Kumar M.D. Weill Cornell Medicine

1:45-2:00: Closing Remarks *Ranjit Deshpande MD FCCM Yale School of Medicine*

2:00: Adjournment

Learning objectives

On completion of this activity the participants will be able to:

1. Compare liver transplantation in India vs the United States
2. Prepare for coagulation and transfusion challenges in liver transplantation
3. Evaluate ex vivo perfusion in liver transplantation.
4. Describe Alcoholic hepatitis and its associated controversies in transplantation.

Target audience

Transplant anesthesiologists, intensivists, transplant surgeons, residents, and fellows.

Organizing committee members:

- Jeron Zerillo, MD (The Mount Sinai Hospital, New York, NY)
- Gebhard Wagener, MD (Columbia University Medical Center, New York, NY)
- Marina Moguevitch, MD (Montefiore Medical Center, Bronx, NY)
- Christine Lennon, MD (Weill Cornell Medicine, New York, NY)
- Joseph Yeh, (NYU Langone, New York, NY)
- Ranjit Deshpande, MD, FCCM (Yale New Haven Hospital, New Haven, CT)
- Tetsuro Sakai, MD, PhD, MHA (University of Pittsburgh Medical Center)

Faculty Listing:

- Akila Rajakumar, MBBS, MD, FRCA; Rela Institute & Medical Centre, Chennai, India
- Gebhard Wagener, MD; Columbia University Irving Medical Center
- James Park, MD; New York University
- Juan P. Rocca, MD; Montefiore Medical Center
- Kevin Fitzmartin MD; Montefiore Medical Center
- Nikhil Chawla, MD; Yale School of Medicine
- Nicole Schlichting, MD; Mount Sinai Medical Center
- Parissa Tabrizian, MD; Mount Sinai Medical Center
- Shreyajit Kumar M.D. Weill Cornell Medicine
- Ted Sakai, MD; University of Pittsburgh Medical Center
- Tricia Brentjens MD; Columbia University Irving Medical Center
- Uyen To MD; Yale School of Medicine

Faculty Disclosure

All individuals in a position to control the content of this education activity including members of the planning committee, speakers, presenters, authors, and/or content reviewers have disclosed all relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

The following relevant financial relationships were disclosed:

- Tetsuro Sakai, MD, PhD, MHA (Book royalty, Springer Inc.)
- Juan P. Rocca, MD Principal investigator for the OCS™ Liver DCD Trial, using the The Portable Organ Care System (OCS™) Liver and the PILOT Study (Perfusion to Improve Liver Outcomes in Transplantation), using the LifePort Liver Transporter (LLT) system.

No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

Accreditation and CME credit designation:

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council of Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician (CME)

The University of Pittsburgh designated this live activity for a maximum of 4.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Healthcare Professionals

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Disclaimer Statement

The information presented at this CME program represents the views and opinions of the individual presenters. It does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for the educational subject matter to be presented in a balanced, unbiased fashion and compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions, including, without limitation, FDA-approved uses and any off-label uses.